EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn’s Disease: A Systematic Review and Meta-analysis

Han Hee Lee, Yuhong Yuan, Brigid S Boland, John T Chang, Vipul Jairath, Siddharth Singh

Clinical Gastroenterology and Hepatology · 2026-04 · 24 (4) · 923-931

DOI: 10.1016/j.cgh.2025.07.009 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-04. Verfasst von Han Hee Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California; Division of Gastroenterology, Departm…. Hauptthemen laut MEDLINE: Crohn Disease. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CSRD VA, NIDDK NIH HHS, NLM NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: We compared the efficacy of different advanced therapies by disease location in patients with Crohn's disease (CD) through a systematic review and meta-analysis. METHODS: Through a systematic review, we identified 14 randomized controlled trials in 3139 patients with moderate-to-severe CD who were treated with different advanced therapies vs placebo, and reported efficacy in inducing clinical remission, stratified by disease location (isolated colonic vs ileal disease, excluding ileocolonic disease). We grouped advanced therapies based on the primary mechanism of action: anti-interleukins, Janus kinase inhibitors (JAK inhibitors), anti-integrins, and tumor necrosis factor (TNF) antagonists. We calculated treatment efficacy (drug vs placebo), overall and by drug class, for colonic vs ileal disease. RESULTS: Overall treatment efficacy of advanced therapies vs placebo was higher in patients with colonic (odds ratio [OR], 4.09; 95% confidence interval [CI], 3.02-5.54) vs ileal CD (OR, 1.80; 95% CI, 1.23-2.63; P < .001). By drug class, anti-interleukins demonstrated a higher efficacy in colonic disease (OR, 4.29; 95% CI, 2.77-6.64) vs ileal disease (OR, 2.31; 95% CI, 1.44-3.70; P = .059), whereas no difference in efficacy was observed with anti-integrins (colonic vs ileal: OR, 1.79; 95% CI, 0.55-5.87 vs 2.10; 95% CI, 0.80-5.53; P = .84). For JAK inhibitors, efficacy was observed only in patients with isolated colonic disease (OR, 4.37; 95% CI, 2.67-7.15), but not in ileal disease (OR, 1.01; 95% CI, 0.54-1.89; P < .001). All analyses had minimal to moderate heterogeneity. CONCLUSIONS: The magnitude of efficacy of advanced therapies for ileal CD is generally lower compared with isolated colonic CD, with JAK inhibitors showing particularly limited efficacy for ileal disease. These results may help inform treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseHumansTreatment OutcomeRemission InductionRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

BiologicsCrohn's DiseaseInflammatory Bowel DiseasesInterleukin InhibitorsJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California; Division of Gastroenterology, Department of Internal Medicine, Yeouido St Mary's Hospital College of Medici…
  • Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
  • Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California.
  • Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California; Department of Medicine, Veterans Affairs San Diego Healthcare System, San Diego, California.
  • Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
  • Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California; Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, C…

Förderung

  • CSRD VA
  • NIDDK NIH HHS
  • NLM NIH HHS
  • US Department of Veterans Affairs
  • Pfizer
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Lee, H. H., Yuan, Y., Boland, B. S., Chang, J. T., Jairath, V., & Singh, S. (2026). Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn’s Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 24(4), 923-931. https://doi.org/10.1016/j.cgh.2025.07.009

Vancouver

Lee HH, Yuan Y, Boland BS, Chang JT, Jairath V, Singh S. Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn’s Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2026;24(4):923-931. doi:10.1016/j.cgh.2025.07.009

BibTeX
@article{Lee2026,
  author = {Lee, Han Hee and Yuan, Yuhong and Boland, Brigid S and Chang, John T and Jairath, Vipul and Singh, Siddharth},
  title = {Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn’s Disease: A Systematic Review and Meta-analysis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {923--931},
  doi = {10.1016/j.cgh.2025.07.009}
}
Kostenlos starten →